TIDMCIZ
RNS Number : 0535P
Cizzle Biotechnology Holdings PLC
16 June 2022
This announcement contains inside information for the purposes
of article 7 of EU Regulation 596/2014 which forms part of domestic
UK law pursuant to the European Union (Withdrawal) Act 2018 ("UK
MAR") . Upon the publication of this announcement this inside
information is now considered to be within the public domain.
16 June 2022
Cizzle Biotechnology Holdings Plc
("Cizzle Biotechnology" or the "Company")
Marketing Agreement to Enhance Expansion in the USA
Cizzle Biotechnology, the UK based diagnostics developer, is
pleased to announce that it has entered into an agreement with the
Behnke Group, a Texas-based healthcare consulting firm with decades
of experience collaborating with healthcare organizations across
the USA and internationally. The relationship will build on Cizzle
Biotechnology's announcement on 6 May 2022 that it had signed a
heads of terms to partner with CorePath Laboratories ("CorePath"),
a full service cancer reference laboratory, to develop and offer
its proprietary early-stage lung cancer test throughout the USA.
The Behnke Group was responsible for identifying and facilitating
the Company's deal with CorePath and the agreement with them is
designed to enhance Cizzle Biotechnology's expansion into the US
markets through the Behnke Group's network of connections in the
clinical and healthcare industry.
Highlights
-- Agreement signed with Behnke Group, USA, to promote, identify
and facilitate partnerships for Cizzle Biotechnology with
healthcare providers and businesses in the USA.
-- The Behnke Group to establish targeted lead generation
campaigns to aid formulating marketing and branding strategies and
work with their network of USA based health systems, clinical
diagnostic and pharmaceutical companies.
-- The Behnke Group will work together with CorePath, a Clinical
Laboratory Improvement Amendments ("CLIA") and College of American
Pathologists ("CAP") accredited laboratory, to assist the
Company.
Background
Lung cancer is the leading cause of cancer death in the USA, in
part because early-stage lung cancer can be asymptomatic, allowing
the disease to progress and resulting in poor 5-year survival
rates*. Currently, there are no simple specific blood tests to
detect lung cancer early when targeted interventions can improve
timely access to cancer care and save lives.
Cizzle Biotechnology is developing a blood test for the early
detection of lung cancer. Its technology is based on the ability to
detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B.
CIZ1 is a naturally occurring cell nuclear protein involved in DNA
replication, and the targeted CIZ1B variant is highly correlated
with early-stage lung cancer.
The Company announced on 6 May 2022 that it had signed a heads
of terms with CorePath to provide the company's CIZ 1B early stage
lung cancer test and the agreement with t he Behnke Group now
provides Cizzle Biotechnology with access to a leading-edge
healthcare consulting group that focusses specifically on companies
with the most innovative and viable products and services to expand
its presence in the USA.
Commenting, Allan Syms, Executive Chairman of Cizzle
Biotechnology, said:
"The USA is a strategically important market for us because of
the high prevalence of lung cancer and the resulting loss of life,
which could be improved through the implementation of a simple
blood test. We are pleased to announce the agreement with the
Behnke Group, who will help build on our partnership with CorePath
Laboratories who are developing our biomarker into a certified
test, and will use their extensive network with hospitals,
clinicians, and the wider healthcare industry to enhance our
presence in the USA. Together we intend to accelerate the wide
adoption of our early-stage cancer detection technology."
Commenting, Bill Behnke, Founder of The Behnke Group, said:
"I recently attended ASCO22, a major clinical sciences
conference in Chicago, USA, where multiple meetings evidenced
considerable interest in Cizzle Biotechnology's entry into the USA.
Cizzle Biotechnology fits perfectly with the Behnke Group's mission
to achieve better outcomes, lower costs and improve the health and
safety of patients. We are excited to add Cizzle Biotechnology to
our portfolio of game changing businesses."
*
https://www.cancer.org/cancer/lung-cancer/detection-diagnosis-staging/survival-rates.html
Enquiries:
Cizzle Biotechnology Holdings Via IFC Advisory
plc
Allan Syms (Executive Chairman)
Allenby Capital Limited +44(0) 20 33285656
John Depasquale
Alex Brearley
Novum Securities Limited +44(0) 20 7399 9400
Colin Rowbury
Jon Bellis
IFC Advisory Limited +44(0) 20 3934 6630
Tim Metcalfe cizzle@investor-focus.co.uk
Florence Chandler
Notes to Editors:
About Cizzle Biotechnology
Cizzle Biotechnology is developing a blood test for the early
detection of lung cancer. Cizzle Biotechnology is a spin- out from
the University of York, founded in 2006 around the work of
Professor Coverley and colleagues . Its proof-of-concept prototype
test is based on the ability to detect a stable plasma biomarker, a
variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell
nuclear protein involved in DNA replication, and the targeted CIZ1B
variant is highly correlated with early-stage lung cancer.
For more information, please see
https://cizzlebiotechnology.com
You can also follow the Company through its twitter account
@CizzlePlc and on LinkedIn.
About the Behnke Group
Founded 2005 by healthcare industry business development
executive Bill Behnke, the Behnke Group is an innovative,
leading-edge healthcare consulting group with proven expertise in
collaborating with a range of healthcare organizations in the U.S.
and internationally in solving today's most important business
challenges. Focusing on companies with the most innovative and
viable products and services with the potential to improve
healthcare, Bill and his team of experienced healthcare industry
professionals provide affordable, scalable, and sustainable
business development strategies that achieve measurable results for
their clients. Please visit: http://behnkegroup.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGRFAMRTMTJBBPT
(END) Dow Jones Newswires
June 16, 2022 02:00 ET (06:00 GMT)
Cizzle Biotechnology (LSE:CIZ)
Historical Stock Chart
From Apr 2024 to May 2024
Cizzle Biotechnology (LSE:CIZ)
Historical Stock Chart
From May 2023 to May 2024